hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06294665 id: MD113/2023 briefTitle: Comparison Between Bupivacaine-Dexmedetomidine Versus Bupivacaine-Dexamethasone in Pericapsular Nerve Group (PENG) Block overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-01 date: 2025-01-01 date: 2024-03-05 date: 2024-03-05 name: Ain Shams University class: OTHER briefSummary: The aim of this work is to compare the effectiveness of bupivacaine- dexmedetomidine mixture versus bupivacaine-dexamethasone mixture in PENG Block as Post-operative Analgesia in Hip surgeries conditions: Hip Fractures conditions: Post Operative Pain studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Pericapsular Nerve Group (PENG) Block measure: The time to the first request of analgesia measure: Total doses of analgesia (Nalbuphine) given to patients in 24 hours postoperatively measure: Occurrence of side effects of drugs. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ain Shams University status: RECRUITING city: Cairo zip: 11122 country: Egypt name: Fatma Ebeid role: CONTACT phone: +201095569596 email: dr.fatma_ebeid@yahoo.com name: Mohamed Salama role: PRINCIPAL_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06294652 id: AGMT_Lymphoma_Reg briefTitle: AGMT Austrian Lymphoma Registry overallStatus: RECRUITING date: 2024-02-27 date: 2033-12-31 date: 2033-12-31 date: 2024-03-05 date: 2024-03-05 name: Arbeitsgemeinschaft medikamentoese Tumortherapie class: OTHER briefSummary: Lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
Lymphoma disease have not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. As lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. Which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus. conditions: Lymphoma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 4000 type: ESTIMATED measure: General Characteristics measure: Genetic Profiling measure: Proportion of lymphoma patients in Austria that require treatment measure: Proportion of lymphoma patients in Austria under active surveillance measure: Number of patients with concomitant diseases measure: Number of treatment and outcome of treatment measure: Patient Outcome measure: Toxicities sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitätsklinik für Innere Medizin III, PMU Salzburg status: RECRUITING city: Salzburg zip: 5020 country: Austria name: Richard Greil, MD role: PRINCIPAL_INVESTIGATOR lat: 47.79941 lon: 13.04399 hasResults: False
nctId: NCT06294639 id: XJA-20240224 briefTitle: ED50 of Esketamine for Laser Treatment in Children acronym: ESCALATE overallStatus: NOT_YET_RECRUITING date: 2024-03-27 date: 2025-03-27 date: 2025-04-27 date: 2024-03-05 date: 2024-03-05 name: Air Force Military Medical University, China class: OTHER briefSummary: There is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. We explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients. conditions: Anesthesia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: The Biased coin method is used primaryPurpose: OTHER masking: NONE maskingDescription: Esketamine will be prepared by an investigator who is not involved in anesthesia and outcome assessment. For all participants, esketamine will be diluted to the same volume. count: 40 type: ESTIMATED name: Esketamine measure: half effective dose of inhibition of body movement measure: number of patients with agitation during awake measure: number of patients with dizzy during awake measure: number of patients with nausea and vomiting during awake measure: number of patients with apnea during awake measure: satisfaction score of the parents to the anesthesia sex: ALL minimumAge: 3 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06294626 id: ISozeri briefTitle: Examination of Neuromotor Development of Cases Diagnosed With Scaphocephaly overallStatus: COMPLETED date: 2019-01-01 date: 2023-12-31 date: 2023-12-31 date: 2024-03-05 date: 2024-03-05 name: Acıbadem Atunizade Hospital class: OTHER briefSummary: It's an observational study. Purpose of the study: To evaluate the neuromotor development of scaphocephaly cases.
Denver-II Developmental Screening Test and Alberta Motor Infant Scale were applied to the participants. conditions: Craniosynostosis, Sagittal conditions: Scaphocephaly conditions: Developmental Delay studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 21 type: ACTUAL name: Group 1 measure: Denver-II Developmental Screening Test measure: Alberta Infant Motor Scale sex: ALL minimumAge: 2 Months maximumAge: 17 Months stdAges: CHILD facility: Acıbadem Altunizade Hospital city: Istanbul state: Uskudar country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06294613 id: CIV-23-07-043672 briefTitle: A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases overallStatus: RECRUITING date: 2024-02-08 date: 2024-07 date: 2024-07 date: 2024-03-05 date: 2024-03-13 name: Acusurgical class: INDUSTRY briefSummary: Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 7 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.
Only one eye per subject can be enrolled. conditions: Vitreoretinal Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 7 type: ESTIMATED name: vitreoretinal surgery measure: Safety Outcome sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UZ Gent status: RECRUITING city: Gent state: East Flanders zip: 9000 country: Belgium name: Bart Leroy, PhD role: CONTACT phone: +32 9 33 25791 email: Bart.Leroy@uzgent.be lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06294587 id: IRB-300012407 briefTitle: Evaluation of Free Gingival Graft Timing overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-07 date: 2027-07 date: 2024-03-05 date: 2024-03-05 name: University of Alabama at Birmingham class: OTHER briefSummary: This clinical trial aims to compare and evaluate the clinical outcomes between two distinct treatment sequences: free gingival graft surgery preceding guided bone regeneration and guided bone regeneration followed by free gingival graft. conditions: Ridge Augmentation conditions: Alveolar Mucosa studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: FGG Before GBR name: FGG after GBR measure: Volumetric outcome assessment measure: Buccal soft tissue profile sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Unversity of Alabama at Birmingham, School of Dentistry city: Birmingham state: Alabama zip: 35294-0007 country: United States name: Hussein Basma, DDS, MS role: CONTACT phone: 205-975-2888 email: basma86@uab.edu name: Sarah Startley, DMD role: CONTACT phone: 205-975-8711 email: ss1971@uab.edu name: Hussein Basma, DDS, MS role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06294574 id: 300011943 briefTitle: Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction overallStatus: NOT_YET_RECRUITING date: 2024-12 date: 2026-12 date: 2026-12 date: 2024-03-05 date: 2024-03-29 name: University of Alabama at Birmingham class: OTHER name: Mammotome briefSummary: The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK. conditions: Breast Neoplasm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: HydroMARK Plus Clip measure: Retrieval rate of the HydroMARK Plus clip. measure: Level of satisfaction of the surgeon with the retrieval of the HydroMARK Plus clip. sex: FEMALE minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Kirklin Clinic city: Birmingham state: Alabama zip: 35249 country: United States name: Quenteeria Mooney role: CONTACT phone: 205-996-1082 email: qmooney@uabmc.edu name: Ceren Yalniz, MD role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06294561 id: TGRX-326-1003 briefTitle: TGRX-326 Pharmacokinetic Drug Interaction overallStatus: RECRUITING date: 2024-03-04 date: 2024-04-30 date: 2024-06-30 date: 2024-03-05 date: 2024-03-08 name: Shenzhen TargetRx, Inc. class: INDUSTRY name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School briefSummary: This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer. conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Itraconazole+TGRX-326 name: Efavirenz+TGRX-326 measure: Plasma Tmax measure: Plasma Cmax measure: Plasma AUC(0-t) measure: Plasma AUC(0-inf) measure: T1/2 measure: Plasma volume of distribution (Vz/F) measure: Plasma clearance (CL/F) measure: Adverse events/serious adverse events measure: Corrected QT Interval sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Nanjing Drug Tower Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210008 country: China name: Juan Li, MD role: CONTACT phone: +862583105910 email: juanli2003@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06294548 id: IRB-300012272 (UAB 23152) briefTitle: A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2027-05-31 date: 2027-12-31 date: 2024-03-05 date: 2024-03-15 name: University of Alabama at Birmingham class: OTHER briefSummary: This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Valemetostat name: Atezolizumab name: Bevacizumab measure: Phase 1b measure: Phase II measure: Safety and pharmacokinetics (PK) measure: Progression free survival (PFS) measure: Overall survival (OS) measure: Duration of response (DoR) measure: Disease Control Rate (DCR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Margaret Thomas, MPH role: CONTACT email: margaretannthomas@uabmc.edu name: Mehmet S Akce, MD role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06294535 id: 2024 briefTitle: The Accuracy of Reconstruction of Orbital Walls Fracture Using Prebent Mesh Versus Patient Specific Implant overallStatus: ENROLLING_BY_INVITATION date: 2023-12-11 date: 2024-05-18 date: 2024-06-06 date: 2024-03-05 date: 2024-03-19 name: Tanta University class: OTHER briefSummary: under GA, incision to access to orbital walls. Then insertion of prebent titanium mesh or customized titanium implant and fixation with miniscrews, examination of ocular motility using forced duction test followed by closure of flap. conditions: Orbital Fractures studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: patient select randomly from closed label whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: reconstruction of orbital walls measure: restoring the accurate position of eye measure: motility of eye measure: volume of orbit sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Faculty of Dentistry, Tanta University city: Tanta zip: 3111 country: Egypt lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06294522 id: 1984 briefTitle: Reconstruction of Nasal Floor for Three-dimensional Repair of Alveolar Cleft overallStatus: COMPLETED date: 2023-07-20 date: 2024-01-06 date: 2024-02-16 date: 2024-03-05 date: 2024-03-19 name: Tanta University class: OTHER briefSummary: reconstruction of alveolar cleft with autogenous bone after elevation of mucoperiosteal flap and suturing of nasal floor and palatal flap conditions: Alveolar Cleft studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 16 type: ACTUAL name: reconstruction of alveolar cleft measure: recurrence of oronasal fistula measure: volume of alveolar cleft after reconstruction measure: density of bone sex: ALL minimumAge: 9 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Faculty of Dentistry, Tanta University city: Tanta zip: 3111 country: Egypt lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06294509 id: SMTaVNS 2024 id: 2024-00039 type: REGISTRY domain: BASEC briefTitle: taVNS Application Timing During Robotic Sensorimotor Task acronym: SMTaVNS2024 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-01 date: 2025-04-01 date: 2024-03-05 date: 2024-03-08 name: Olivier Lambercy class: OTHER briefSummary: The goal of this clinical trial is to evaluate the feasibility and effectiveness of transcutaneous auricular vagus nerve stimulation (taVNS) in enhancing sensorimotor learning and adaptation. This study will focus on healthy individuals performing a robotic sensorimotor task.
Researchers will compare the four experimental groups to each other to see if different taVNS stimulation timings affect sensorimotor learning outcomes, as well as to a control group that will receive no stimulation. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single-blinded, pseudo-randomised, exploratory, single-centre, national, longitudinal study primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 75 type: ESTIMATED name: in-house developed transcutaneous auricular Vagus Nerve Stimulation device measure: Subjectively perceived tolerance of taVNS and perceived difficulty of motor task measure: Success of the sensorimotor challenge measure: Mean Change from Baseline in Galvanic Skin Response (GSR) measure: Mean Change from Baseline in Heart Rate (HR) measure: Mean Change from Baseline in Pupil Diameter (PD) measure: Mean Change from Baseline in electroencephalogram (EEG) measure: Subjectively perceived positive effects of taVNS on motor performance measure: Change of movement parameters from baseline measure: Associations between outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06294496 id: 2023YFS0274 briefTitle: Study of Carotid Artery Stenosis Through the Integration of Multimodal Imaging and Computational Fluid Dynamics overallStatus: RECRUITING date: 2023-06-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-05 date: 2024-03-05 name: Sichuan Provincial People's Hospital class: OTHER briefSummary: Ischemic stroke affects 2.5 to 3 million people annually in China, ranking as the leading cause of death and disability. Cervical artery stenosis is a significant contributor to this problem, with about 50% of patients experiencing cognitive impairment due to reduced cerebral blood flow. Two main surgical approaches, carotid endarterectomy (CEA) and carotid artery stenting (CAS), are used to treat severe cervical artery stenosis, but their effects on various factors remain unclear.
This project collects multimodal imaging data, including CT perfusion and angiography, to create 3D models of cervical artery stenosis. Computational fluid dynamics and AI analysis are used to assess hemodynamics. By monitoring blood flow, oxygen levels, and evaluating postoperative outcomes, the goal is to tailor surgical approaches for better patient outcomes and improved quality of life. conditions: Carotid Stenosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: CEA/CAS measure: Perioperative cardio-cerebrovascular adverse events measure: Compute fluid dynamics parameters measure: Clinical outcome sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sichuan Provincial People's Hospital status: RECRUITING city: Chengdu state: Sichuan zip: 610072 country: China name: Li Xiong, Master role: CONTACT phone: 028-87393020 email: lcl1206778081@163.com name: Chaoqun Zeng, Ph.D. role: SUB_INVESTIGATOR lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06294483 id: Soh-Med-24-01-09MS briefTitle: Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. overallStatus: ENROLLING_BY_INVITATION date: 2024-01-10 date: 2024-07-30 date: 2024-08-30 date: 2024-03-05 date: 2024-03-05 name: Sohag University class: OTHER briefSummary: The present study aims to:
Evaluate the relationship between hematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and Systemic lupus erythematosus (SLE) disease manifestations and activity. conditions: Systemic Lupus Erythematosus studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: CBC name: Antinuclear Antibody tests (ANA) name: Rest of ANA profile name: C3 and C4 complement level. name: Anti phospholipid marker name: Serum creatinine and Alb/create ratio name: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. name: SLEDAI scores measure: Evaluate the hematological indices as (mean platelet volume) of our SLE patient. measure: Evaluate the hematological indices as (neutrophil lymphocyte ratio) of our SLE patient. measure: Evaluate the hematological indices ( platelet lymphocyte ratio ) of our SLE patient. measure: Compare the degree of disease activity between the early-onset and late-onset patients with systemic lupus erythematosus. measure: Evaluate the correlation between hematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and Systemic lupus erythematosus (SLE) disease manifestations and activity. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag university hospital city: Sohag country: Egypt lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06294470 id: 01-2023 briefTitle: Efficacy of Stapled Hemorrhoidopexy for the Treatment of Obstructive Defecation Syndrome overallStatus: COMPLETED date: 2023-05-01 date: 2023-11-30 date: 2023-12-15 date: 2024-03-05 date: 2024-03-05 name: Universidad Central de Venezuela class: OTHER briefSummary: The objective of this study is to assess the efficiency of the procedure for hemorrhoidal prolapse and pexia in alleviating symptoms of defecatory obstruction among patients with grade II to IV mucohemorrhoidal prolapse. conditions: Hemorrhoids conditions: Defecation Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 34 type: ACTUAL name: Ballon expulsion test name: Colonic transit time name: Stapled hemorrhodopexy measure: Postoperative improvement of symptoms of defecatory obstruction measure: Postoperative change of the balloon expulsion test measure: Postoperative change of the colonic transit time sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Domingo Luciani city: Caracas state: Miranda zip: 1073 country: Venezuela lat: 10.48801 lon: -66.87919 hasResults: False
nctId: NCT06294457 id: CI-2024-480 briefTitle: Effectiveness of Non-invasive Neuromodulation for Intestinal Transit in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-03 date: 2024-06 date: 2024-03-05 date: 2024-03-05 name: Universidad Europea de Madrid class: OTHER briefSummary: Objectives
Evaluate the improvement in sleep quality Analyze the improvement in blood pressure quality Measure the improvement in cortisol quality Determine if there is an improvement in heart rate conditions: Constipation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: The device will be placed with no current. This type of neuromodulation gives no feeling at all to the patient while administred, so there is no way for the patient to know if the apparatus is connected or not. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Non-Invasive Neuromodulation NESA measure: Quality of life by constipation (CVE-20) measure: Sleep Quality measure: Cardiac Frecuency measure: Arterial pressure sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False